RT Journal Article
T1 Proprotein convertase subtilisin/kexin type 9 inhibitors in secondary prevention of vascular events in patients with stroke: Consensus document and practice guidance.
T2 Inhibidores de la proproteína convertasa subtilisina/kexina tipo 9 (iPCSK9) en la prevención secundaria de episodios vasculares en pacientes con ictus isquémico: Documento de consenso y aplicaciones prácticas.
A1 Gil-Núñez, A
A1 Masjuan, J
A1 Montaner, J
A1 Castellanos, M
A1 Segura, T
A1 Cardona, P
A1 Tembl, J I
A1 Purroy, F
A1 Arenillas, J
A1 Palacio, E
K1 Cerebrovascular disease
K1 Colesterol LDL
K1 Dislipemia
K1 Dyslipidemia
K1 Enfermedad cerebrovascular
K1 Ictus
K1 LDL cholesterol
K1 Prevención secundaria
K1 Secondary prevention
K1 Stroke
AB Patients with history of stroke or transient ischaemic attack present considerable risk of future vascular events. Reducing levels of low-density lipoprotein (LDL) cholesterol decreases the incidence of new vascular events, although in a substantial number of patients, the currently available lipid-lowering therapies fail to achieve the therapeutic goals recommended in clinical guidelines. The aim of this consensus statement is to provide updated information on the role of the proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors alirocumab and evolocumab in the secondary prevention of vascular events in patients with history of ischaemic stroke. A literature review was performed to identify the main evidence on the use of PCSK9 inhibitors in these patients and the recommended therapeutic targets of LDL cholesterol. The results were discussed in 2 consensus meetings that constituted the basis for the drafting of the document. PCSK9 inhibitors are effective in reducing vascular risk in secondary prevention; evolocumab specifically has achieved this reduction in patients with history of ischaemic stroke. Moreover, both alirocumab and evolocumab present good safety profiles, even in patients achieving LDL cholesterol levels
YR 2020
FD 2020-12-21
LK http://hdl.handle.net/10668/22445
UL http://hdl.handle.net/10668/22445
LA en
LA es
DS RISalud
RD Apr 20, 2025